0

Methylsulfonylmethane for Treatment of Low Back Pain: A Safety Analysis of a Randomized, Controlled Trial

Paul Crawford, Amanda Crawford, Frederick Nielson, Robert Lystrup

Complement Ther Med. 2019 Aug;45:85-88.

PMID: 31331587

Abstract:

Objective:
To ensure that 16 weeks of methylsulfonylmethane (MSM) does not cause adverse effects in patients with the musculoskeletal disorders of osteoarthritis and back pain.
Design:
We carried out a subgroup analysis on data from a randomized, double-blind, placebo-controlled trial, "The use of Methylsulfonylmethane (MSM) in the treatment of low back pain," to determine the safety of taking 6 g daily of MSM (OptiMSM®, Bergstrom Nutrition). We monitored metabolic parameters to determine whether MSM altered hematologic, liver or kidney function. We also monitored physiologic parameters of blood pressure and weight.
Setting:
Family Medicine Residency, Mike O'Callaghan Military Medical Center.
Main outcome measures:
Metabolic parameters as measured by hematologic function - white blood cells (WBC), platelets, hemoglobin (Hb), glucose; liver function as measured by - total bilirubin, alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Physiologic parameters as measured by weight, diastolic (DBP) and systolic blood pressure (SBP); kidney function as measured by creatinine.
Results:
Analysis of outcome measures showed no significant difference between MSM and placebo (p < 0.05) safety values.
Conclusion:
MSM has no effects on WBC, platelets, Hb, total bilirubin, AST, ALT, creatinine weight, DBP, or SBP in this study.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP67710-C Methylsulfonylmethane Methylsulfonylmethane 67-71-0 Price
qrcode